Last reviewed · How we verify
JMKX003948 Ophthalmic Suspension
JMKX003948 Ophthalmic Suspension is a Small molecule drug developed by Jemincare. It is currently in Phase 1 development.
At a glance
| Generic name | JMKX003948 Ophthalmic Suspension |
|---|---|
| Sponsor | Jemincare |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- JMKX003948 Ophthalmic Suspension CI brief — competitive landscape report
- JMKX003948 Ophthalmic Suspension updates RSS · CI watch RSS
- Jemincare portfolio CI
Frequently asked questions about JMKX003948 Ophthalmic Suspension
What is JMKX003948 Ophthalmic Suspension?
JMKX003948 Ophthalmic Suspension is a Small molecule drug developed by Jemincare.
Who makes JMKX003948 Ophthalmic Suspension?
JMKX003948 Ophthalmic Suspension is developed by Jemincare (see full Jemincare pipeline at /company/jemincare).
What development phase is JMKX003948 Ophthalmic Suspension in?
JMKX003948 Ophthalmic Suspension is in Phase 1.
Related
- Manufacturer: Jemincare — full pipeline
- Compare: JMKX003948 Ophthalmic Suspension vs similar drugs
- Pricing: JMKX003948 Ophthalmic Suspension cost, discount & access